Egle Therapeutics, EGL-003, Treg, Regulatory T Cells, IL-2 Agonist, IL-2 Mutein, Atopic Dermatitis, Autoimmune Disease, EADV 2026, Phase 1, Phase 2, Multiple Ascending Dose

Advertisement

cGxPJobs Banner

Advertisement

cGxPJobs

Start typing and press Enter to search